Genprex GNPX Stock News

Genprex Inc (NASDAQ: GNPX) is making a run for the top in the market today, and for good reason. The company announced that it has signed an exclusive worldwide agreement with Texas MD Anderson Cancer Center. Here’s what you need to know:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

GNPX Stock Is Running For The Top On License Agreement

In the press release, Genprex said that it signed a Patent and Technology License Agreement with The University of Texas MD Anderson Cancer Center. Under the terms of the agreement, MD Anderson has granted the company an exclusive worldwide license to 16 patent applications and related technology.

In particular, these patent applications and technologies are centered around the treatment of cancer using Oncoprex, the lead drug candidate at GNPX. In particular, the assets relate to the use of Oncoprex in combination with targeted therapeutics like osimertinib.

In the release, the company reminded investors that it recently received FDA Fast Track designation for Oncoprex combined with Tagrisso for the treatment of non-small cell lung cancer patients.

The company is also in the midst of preparing an IND to move forward with a clinical trial of Oncoprex in combination with Keytruda as a potential option for NSCLC patients.

In a statement, Rodney Varner, CEO at GNPX, had the following to offer:

We are pleased to advance the intellectual property that is covered by this License Agreement. We are excited to be developing two distinct therapeutic approaches to lung cancer utilizing the combination of our gene therapy with successful targeted therapies, such as Tagrisso, and immunotherapies, such as Keytruda, to potentially improve patient outcomes and increase the number of patients who may benefit from these important therapies.

Why This Is Big News

Genprex is making strides here. First and foremost, there’s strong clinical evidence that when you combine immunotherapies that change tumor microenvironments and enhance the body’s innate immune system with targeted therapies, patients with various forms of cancer can see positive outcomes.

With the data released surrounding Oncoprex, GNPX has something of real value here, especially when combined with targeted therapies. Due to the licensing agreement announced today, the company now has the full right to move forward with the development of key combination therapies using its lead candidate.

Should all go well, the revenue potential is incredible. Think about it, experts suggest that the NSCLC market can grow to be worth well over $10 billion annually in just a few years. And that’s just one of the markets that Oncoprex is showing promise in. Ultimately, these patents change the game. So, there’s good reason to be excited about GNPX.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Don’t Miss The Next Big Move

Join our free mailing list below to receive alerts!

Subscribe Today!

* indicates required


LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.